Laverock Therapeutics Reports Key Oncology Research Milestones
Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo functional milestones across its T-cell and macrophage oncology programmes for solid tumour indications. The data support lead programme selection and progression towards the clinic.
Laverock Therapeutics Awarded in Excess of £2.2M Through Two Innovation Grants to Support AI-powered Platform Development and to Expand Therapeutic Programmes Outside of Oncology
Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced it has been awarded two new grants totalling in excess of £2.2M to support the next generation of its gene-control platform development, and expansion into additional non-oncology therapeutics areas.
